CTI BioPharma price target lowered to $8 from $10 at TD Cowen

TD Cowen analyst Boris Peaker lowered the firm’s price target on CTI BioPharma to $8 from $10 and keeps an Outperform rating on the shares. The analyst said we are updating our model and corresponding estimates as VONJO sales have been slower than initially anticipated.